کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5609991 | 1577830 | 2012 | 12 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Use of Echocardiography to Evaluate the Cardiac Effects of Therapies Used in Cancer Treatment: What Do We Know?
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ACEARBDTILVEFIVRTAngiotensin-converting enzyme - آنژیوتانسین تبدیل آنزیمechocardiography - اکوکاردیوگرافیLeft ventricular - بطن چپDoppler tissue imaging - تصویربرداری بافت داپلرIsovolumic relaxation time - زمان آرامش IsovolumicCardiotoxicity - سمیت قلبیChemotherapy - شیمیدرمانیlongitudinal strain - فشار طولیAngiotensin receptor blocker - مسدود کننده گیرنده آنژیوتانسینheart failure - نارسایی قلبیleft ventricular ejection fraction - کسر خروجی بطن چپ
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Cardiologists and oncologists today face the daunting challenge of identifying patients at risk for late-onset left ventricular (LV) systolic dysfunction from the use of various chemotherapeutic agents. Currently, the most widely used method in clinical practice for monitoring the potential of chemotherapy-induced cardiotoxicity is calculation of LV ejection fraction. The use of LV ejection fraction to determine whether to continue or discontinue the use of chemotherapeutic agents is limited, because decreases in LV ejection fraction frequently occur late and can be irreversible. These limitations have led to the exploration of diastolic function and newer modalities that assess myocardial mechanics to identify sensitive and specific variables that can predict the occurrence of late systolic function. The cancer therapies associated with cardiotoxicity are reviewed in this report. Additionally, the authors evaluate the role of present-day echocardiographic parameters, complementary noninvasive imaging modalities, and biomarkers in the prediction of cardiotoxicity. The authors address the evolving role of cardioprotective agents and potential therapies to prevent or reverse the progression of LV systolic dysfunction. Finally, they provide some ideas regarding future directions to enhance the knowledge of predicting late-onset LV systolic dysfunction secondary to cancer therapy.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of the American Society of Echocardiography - Volume 25, Issue 11, November 2012, Pages 1141-1152
Journal: Journal of the American Society of Echocardiography - Volume 25, Issue 11, November 2012, Pages 1141-1152
نویسندگان
Lilia MD, Maria Chiara MD, Matt M. RDCS, FASE, Christopher RDCS, Rubina MD, Scipione MD, FESC, Bijoy K. MD, FACC, FESC, FASE, FAHA, FACP, Timothy E. MD, JD, FASE, FACC,